Camden, Delaware – January 23, 2025 – NormaxBio, a pioneering biotechnology company at the forefront of innovative immunotherapies, today announced a strategic partnership with Prestel & Partner, the global leader in Family Office Forums. This collaboration will see NormaxBio’s groundbreaking Educated Antigen Receptor Therapy (EARTh) for People Living with Cancer featured at nine prestigious family office events worldwide. NormaxBio’s EARTh therapy represents a significant leap forward in personalized cancer treatment. This innovative [...]

Normax Biomed has launched a capital raise campaign for up to £15 million in Series A funding for the deployment of Educated Antigen Receptor Therapy (EARTh) GMP Process for personalized mRNA cancer vaccine production in GMP clean room located in the Medical Technology Innovation Center (MTIF) at Nottingham Trent University Clifton Campus May 13, 2024, 12:00 PM Greenwich Mean Time (GMT) - PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER. Nottingham, UK – [...]

The collaboration agreement with Normax Biomed Ltd, will enable The Medical Technologies Innovation Facility at Nottingham Trent University to accelerate the development and discovery of new mRNA vaccines and gene therapies. 24 January 2023 – Normax Biomed Limited (“Normax”) has launched a partnership with the Medical Technologies Innovation Facility (MTIF) at Nottingham Trent University (NTU) to offer access to its BioXPTM system by Telesis Bio Inc. and to innovate in RNA [...]

Normax plans to use capital finance to scale mRNA Vaccine Research and Development with Vax Factory Manufacturing for Transformative Social Impact on Infectious Diseases, Rare Diseases, Cancers and Pandemic Preparedness July 11, 2022, 12:00 PM Greenwich Mean Time (GMT) - PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER. DUBLIN, Ireland -- The mRNA vaccine technology company Normax Biomed Limited (“Normax”), today announced a €300 Million investment commitment from GEM Global Yield LLC SCS (“GEM”), [...]